Karaciğer Nakli Sonrası Akut Antikor Aracılı Rejeksiyon: Tanı ve Tedavi

Faguer S & et al. (2007). Rituximab therapy for acute humoral rejection after kidney transplantation. Transplantation 83:1277.
White NB & et al. (2004). Successful rescue therapy with plasmapheresis and intravenous immunoglobulin for acute humoral renal transplant rejection. Transplantation 78:772.
Demetris AJ & et al. (2016). Functional immune anatomy of the liver-as an allograft. Am J Transplant;16:1653e80.
Demetris AJ & et al. (2015). ABO-compatible liver allograft antibody-mediated rejection: an update. Curr Opin Organ Transplant;20:314e24.
Gugenheim J & et al. (1990). Specific absorption of lymphocytotoxic alloantibodies by the liver in inbred rats. Transplantation;50:309–313.
Astarcioglu I & et al. (1999). Increased risk of antibodymediated rejection of reduced-size liver allografts. J Surg Res; 87:258–262.
Everly MJ & et al. (2008). . Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation;86:1754–1761.
Yalçın B. (2013). Major histocompatibility complex (MHC) molecules: their common characteristics and relations with diseases. Turkderm-Turk Arch Dermatol Venereol.; 47(1): 12-17 DOI: 10.4274/turkderm.47.s2.
Peter T.W. Kim & et al. (2016). Prevention and treatment of liver allograft antibody-mediated rejection and the role of the ‘two-hit hypothesis’. Curr Opin Organ Transplant, 21:209–218.
Ramirez RS & et al. (2022). Antibody-mediated rejection: prevention, monitoring and treatment dilemmas. Curr Opin Organ Transplant . 2022 Oct 1;27(5):405-414.
Del Bello A & et al. (2016). Donor-specific antibodies and liver transplantation. Human Immunology 77 (2016) 1063–1070.
Taner T, Stegall MD & Heimbach JK. (2014). Antibody-mediated rejection in liver transplantation: current controversies and future directions. Liver Transpl;20(5):514-27.
Demetris AJ & et al. (2016). Comprehensive Update of the Banff Working Group on Liver Allograft Pathology: Introduction of Antibody-Mediated Rejection. Am J Transplant. 16:2816–35. doi: 10.1111/ajt.13909.
Aguilera I & et al. (2011). Complement component 4d immunostaining in liver allografts of patients with de novo immune hepatitis. Liver Transpl;17(7):779-88.
Hogen R, DiNorcia J & Dhanireddy K. Antibody-mediated rejection: what is the clinical relevance? Curr Opin Organ Transplant 2017, 22:97–104.
Cuadrado A & et al. (2015). Clinical significance of donor-specific human leukocyte antigen antibodies in liver transplantation. . World J Gastroenterol; 21(39): 11016-11026.
Amore A. (2015). Antibody-mediated rejection. Curr Opin Organ Transplant 2015, 20:536–542.
Kaneku H & et al. (2013). De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients. Am J Transplant; 13: 1541-1548.
Turgeon NA, Kirk AD & Iwakoshi NN. (2009). Differential effects of donorspecific alloantibody. Transplant Rev; 23: 25-33.
. Pascual M & et al. (1998). Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation. Transplantation; 11:1460–1464.
. Musat AI & et al. (2011). The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation. Am J Transplant; 11:500–510.
Billing H & et al. (2012). . IVIG and rituximab for treatment of chronic antibodymediated rejection: a prospective study in paediatric renal transplantation with a 2-year follow-up. Transpl Int; 25:1165–1173.
Paterno F & et al. (2012). Bortezomib for acute antibody-mediated rejection in liver transplantation. Am J Transplant; 12: 2526-2531.